[Using mouse model to evaluate the immune effect of DNA prime-protein boost strategies targeting Japanese encephalitis virus].

Sheng Wu Gong Cheng Xue Bao

State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, Gansu, China.

Published: August 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In order to evaluate the immune effect of the genotype Ⅰ Japanese encephalitis virus prM-E DNA vaccine and the prM-EⅢ fusion protein subunit vaccine on mice using DNA prime-protein boost strategy, the prM-E gene was inserted into the pVAX1 eukaryotic expression vector. The recombinant expression vector prM-E-pVAX1 was constructed as a DNA vaccine for initial immunity, and the recombinant prM-EⅢ fusion protein was obtained using a prokaryotic expression system as a subunit vaccine for enhanced immunity. Thirty two female BALB/c mice aged 4-6 weeks were randomly divided into four groups, and a prM-E-pVAX1 DNA vaccine group, a DNA prime-protein boost immune group, a prM-EⅢ subunit vaccine group, and a pVAX1 vector control group were set up. The specific antibody level in serum was monitored by ELISA, the neutralizing antibody titer was detected by plaque reduction neutralization, and the cellular immune responses induced by different vaccine immune groups were analyzed by cytokine expression abundance and lymphocyte proliferation experiments. The results showed that the neutralizing antibody titers induced by mice immunized with the DNA prime-protein boost strategy were close to that of the group immunized with the single prM-EⅢ subunit vaccine, but significantly higher than that of the group immunized with the single prM-E-pVAX1 DNA vaccine. DNA prime-protein boost strategies induced effective Th1/Th2 immune responses in mouse models, in particular the Th1 cell-mediated immune responses. This study provides a new immune strategy that may facilitate the prevention of Japanese encephalitis.

Download full-text PDF

Source
http://dx.doi.org/10.13345/j.cjb.220160DOI Listing

Publication Analysis

Top Keywords

dna prime-protein
20
prime-protein boost
20
dna vaccine
16
subunit vaccine
16
japanese encephalitis
12
immune responses
12
dna
9
vaccine
9
immune
8
evaluate immune
8

Similar Publications

Developing an effective HIV vaccine is a momentous challenge. An exceptionally wide range of candidate HIV vaccines have been tested, yet many were poorly immunogenic, and of the select few that advanced into efficacy trials, only one demonstrated any efficacy. Here we report the results of the largest-scale cross-protocol immunogenicity comparison to date: 13 HIV vaccine trials (including 36 vaccine regimens) conducted across nine countries worldwide, strengthened by standardized trial designs, validated assays in centralized laboratories, and harmonized immunogenicity endpoints - providing an objective approach to identify the HIV vaccine candidate(s) with the best immunogenicity.

View Article and Find Full Text PDF

Preventing immune escape of SARS-CoV-2 variants is crucial in vaccine development to ensure broad protection against the virus. Conformational epitopes beyond the RBD region are vital components of the spike protein but have received limited attention in the development of broadly protective SARS-CoV-2 vaccines. In this study, we used a DNA prime-protein boost regimen to evaluate the broad cross-neutralization potential of immune response targeting conformational non-RBD region against SARS-CoV-2 viruses in mice.

View Article and Find Full Text PDF

Introduction: The development of effective vaccines against is critical due to its significant impact on human and animal health. The objective of this study was to design and evaluate and a multivalent vaccine based on the immunogenic potential of three selected open reading frames (ORFs) of .

Methods: The designed construct, named S22, was analyzed to evaluate its physicochemical properties, antigenicity, allergenicity and toxicity.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on the challenge of generating tier-2-neutralizing antibodies for HIV vaccines, highlighting the isolation of a specific antibody, HmAb64, from an immunized individual.
  • HmAb64 is characterized by its unique genetic structure, derived from germline genes, and was shown to neutralize 10% of the tested HIV-1 pseudo-virus strains.
  • The research also reveals the structural details of how HmAb64 binds to the CD4-binding site, proving that a gp120-based vaccine can effectively stimulate the production of antibodies capable of neutralizing tier-2 HIV strains.
View Article and Find Full Text PDF

Background: Heterologous combinations in vaccine design are an effective approach to promote T cell activity and antiviral effects. The goal of this study was to compare the homologous and heterologous regimens targeting the Nef-Tat fusion antigen to develop a human immunodeficiency virus-1 (HIV-1) therapeutic vaccine candidate.

Methods: At first, the DNA and protein constructs harboring HIV-1 Nef and the first exon of Tat as linked form (pcDNA- and Nef-Tat protein) were prepared in large scale and high purity.

View Article and Find Full Text PDF